Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

cannabis/atrophy

Link salvestatakse lõikelauale
6 tulemused

Cannabinoid receptor modulators

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Application under 35 U.S.C. .sctn.371 of International Application No. PCT/US2010/002360, filed Aug. 27, 2010, which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application Nos. 61/275,506, filed Aug.

Cannabinoid receptor modulators

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions

Crystalline forms and processes for the preparation of cannabinoid receptor modulators

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclop- ropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that

Crystalline forms and processes for the preparation of cannabinoid receptor modulators

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclop- ropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that

Cannabinoid-containing plant extracts as neuroprotective agents

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
RELATED APPLICATIONS This application is a national stage filing under 35 U.S.C. .sctn. 371 of international application PCT/GB2007/000122, filed Jan. 17, 2007, which was published under PCT Article 21(2) in English. FIELD OF THE INVENTION The present invention relates to the use of

Cannabinoid-containing plant extracts as neuroprotective agents

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. BACKGROUND TO THE INVENTION Neural degeneration, or neurodegeneration, can be described as the progressive damage or death of neurones.
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge